Lanean...

Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse

Tyrosine kinase inhibitors have dramatically improved the treatment of chronic myeloid leukemia. Recent evidence revealed that some patients with chronic myeloid leukemia can stop imatinib without relapse after achieving a complete molecular response. This review discusses the possible predictive ma...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yoshimoto, Takayuki, Mizoguchi, Izuru, Katagiri, Seiichiro, Tauchi, Tetsuzo, Furusawa, Jun-ichi, Chiba, Yukino, Mizuguchi, Junichiro, Ohyashiki, Junko H, Ohyashiki, Kazuma
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Landes Bioscience 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4091524/
https://ncbi.nlm.nih.gov/pubmed/25057448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/onci.28861
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!